Table 1 Baseline characteristics of the patients included in the Clinical Trial

Age (y)

30.7 ± 7.3 (21–40)

31.0 ± 5.6 (24–40)

33.6 ± 4.0 (26–40)

30.4 ± 8.2 (20–40)

Parity ≥ 1

3 (37.5%)

1 (14.3%)

5 (55.5%)

0 –

Infertility

0 –

1 (14.3%)

1 (11.1%)

1 (14.3%)

Antecedents

a. Endometriosis, MST

1 (12.5%)

1 (14.3%)

2 (22.2%)

2 (28.6%)

b. Endometriosis + myomas

1 (12.5%)

1 (14.3%)

0 –

0 –

c. Endometriosis-OCP

0 –

1 (14.3%)

0 –

2 (28.6%)

Symptoms: VAS/10

5.6 ± 1.6 (3–8)

6.1 ± 2.0 (4–9)

5.6 ± 2.2 (3–9)

4.7 ± 2.1 (3–8)

Dysmenorrhea/3

2.1 ± 0.2 (2–2.5)

2.1 ± 0.6 (1.5–3)

1.7 ± 0.6 (0.5–2)

1.8 ± 0.9 (0.5–2.5)

Dyspareunia/3

(7) 1.1 ± 0.9 (0.5–3)

1.6 ± 1.1 (0–3)

1.4 ± 1.0 (0–3)

(4) 0.9 ± 1.0 (0–2)

CPP/3

1.7 ± 0.9 (0–2.5)

1.4 ± 0.8 (0.5–2.5)

1.7 ± 1.0 (0–3)

1.8 ± 1.5 (0–3)

Trasvaginal US/ovaries

a. Endometriomas, RO

2 (25%)

0 –

4 (44.4%)

0 –

b. Endometriomas LO

2 (25%)

3 (42.8%)

2 (22.2%)

5 (71.4%)

c. Bilateral/kissing ovaries/rvs

4 (50%)

4 (57.1%)

3 (33.3%)

2 (28.6%)

Analysis

CA-125

80.5 ± 57.8 (36–190)

90.4 ± 37.6 (37–150)

56.3 ± 12.9 (36–70.4)

87 ± 42 (53–168)

CA-19-9

44.9 ± 63.5 (9.5–198)

(6)58.9 ± 71 (2–191)

(8)38 ± 19.4 (11–66)

(6)36.6 ± 37 (11–111)

Diagnosis

a. Endometrioma, RO

1 (12.5%)

0 –

3 (33.3%)

0 –

b. Endometrioma, LO

1 (12.5%)

3 (42.8%)

2 (22.2%)

4 (57.1%)

c. Pelvic endometriomas

6 (75%)

4 (57.1%)

3 (33.3%)

3 (42.8%)

d. Recurrent endomet/rvs

0 –

0 –

1 (11.1%)

0 –

Surgery

a. TUGPA

0 –

7 (100)

0 –

7 (100)

b. Laparoscopy, CS

7 (87.5%)

0 –

6 (66.7%)

0 –

c. Laparotomy, CS

1 (12.5%)

0 –

3 (33.3%)

0 –

Findings in CS

a. Endometriomas

4 (50%)

–

5 (55.5%)

–

b. Severe pelvic endomet + end-omas

3 (37.5%)

–

4 (44.4%)

–

c. Endometriomas + myoma

1 (12.5%)

–

0 –

–

Histopathology

a. Cytology compatible with endometriosis

–

7 (100)

–

7 (100)

b. Endometriosis (cystic)

8 (100) (1 + Myo)

0 –

7 (77.7%)

0 –

c. Atypical endometriosis

0 –

0 –

2 (22.2%)

0 –